Diseases [C] » Immune System Diseases
Description
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. MeSH
Hierarchy View
Subtype Terms (11)
Autoimmune Diseases
131 drugs (87 approved, 44 experimental)
Erythroblastosis, Fetal
4 drugs (2 approved, 2 experimental)
Glomerulonephritis, Membranoproliferative
12 drugs (7 approved, 5 experimental)
Graft vs Host Disease
252 drugs (141 approved, 111 experimental)
Hypersensitivity
163 drugs (79 approved, 84 experimental)
Immune Reconstitution Inflammatory Syndrome
7 approved drugs
Immunologic Deficiency Syndromes
23 drugs (19 approved, 4 experimental)
Immunoproliferative Disorders
16 drugs (9 approved, 7 experimental)
Mast Cell Activation Disorders
3 experimental drugs
Purpura, Thrombocytopenic
9 approved drugs
Transfusion Reaction
10 drugs (5 approved, 5 experimental)
Approved Indicated Drugs (1)
Phase 2 Indicated Drugs (51)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
Phase 1 Indicated Drugs (16)
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (31)
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (12)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
